4//SEC Filing
Protalix BioTherapeutics, Inc. 4
Accession 0001178913-14-002978
$PLXCIK 0001006281operating
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 6:00 PM ET
Size
8.0 KB
Accession
0001178913-14-002978
Insider Transaction Report
Form 4
Bronfeld Zeev
Director10% Owner
Transactions
- Other
Common Stock
2014-09-16−8,556,371→ 1,509,948 total(indirect: By Trust) - Other
Common Stock
2014-09-16+1,838,109→ 1,838,109 total
Footnotes (6)
- [F1]Biocell Ltd. distributed 8,554,988 shares of common stock of Protalix BioTherapeutics, Inc., in a dividend to its shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. Biocell Ltd. is an Israeli public company traded on the Tel Aviv Stock Exchange Ltd.
- [F2]The shares were transferred to the Biocell Ltd. shareholders on a pro rata basis based on their respective percentage interests in Biocell Ltd. No consideration was paid in connection with the transfer.
- [F3]All shares of Protalix BioTherapeutics, Inc. common stock are held by Biocell Ltd. Mr. Bronfeld disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- [F4]Substantially all of the shares of Protalix BioTherapeutics, Inc. common stock held by Biocell Ltd. following the dividend reported in this Form 4 are held in a trust for the benefit of Biocell Ltd.
- [F5]The reporting person, a shareholder of Biocell Ltd., received shares of Protalix BioTherapeutics, Inc. common stock pursuant to the dividend made by Biocell Ltd. described in this Form 4. The shares received are limited to the reporting person's percentage interest in Biocell Ltd. The reporting person continues to hold such shares.
- [F6]No consideration was paid in connection with the transfer.
Documents
Issuer
Protalix BioTherapeutics, Inc.
CIK 0001006281
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001006281
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 6:00 PM ET
- Size
- 8.0 KB